| 1. |
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat，2004, 11(2): 97-107.
|
| 2. |
Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatol，2006, 45(4): 529-538.
|
| 3. |
Murray KF, Carithers RL, Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation[J]. Hepatology，2005, 41(6): 1407-1432.
|
| 4. |
Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma[J]. Semin Liver Dis，2005, 25 （Suppl 1）：40-47.
|
| 5. |
中華醫學會肝病學分會, 中華醫學會感染病學分會. 慢性乙型肝炎防治指南(2010年版)[J]. 中國預防醫學雜志， 2011, 12(1): 1-15.
|
| 6. |
Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterology, 2003, 124(1): 105-117.
|
| 7. |
Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology，2010, 52(3): 886-893.
|
| 8. |
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med，2004, 351(15): 1521-1531.
|
| 9. |
Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B[J]. Hepatology，2000, 31(1): 207-210.
|
| 10. |
Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection[J]. J Hepatol，2000, 33(2): 301-307.
|
| 11. |
Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J]. Hepatology，2001, 33(2): 424-432.
|
| 12. |
Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort[J]. Hepatology，2001, 34(2): 411-416.
|
| 13. |
Bae SH, Yoon SK, Choi JY, et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis[J]. J Gastroenterol Hepatol，2005, 20(10): 1527-1532.
|
| 14. |
Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy[J]. Gastroenterology，2002, 123(3): 719-727.
|
| 15. |
Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease[J]. J Hepatol， 2010, 53(1): 118-125.
|
| 16. |
Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients[J]. Hepatology，2003, 38(6): 1419-1427.
|
| 17. |
Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results[J]. Liver Transpl，2007, 13(3): 349-360.
|
| 18. |
Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol，2010, 52(2): 176-182.
|
| 19. |
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study[J]. Hepatology，2011, 54(1): 91-100.
|
| 20. |
Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis[J]. J Viral Hepat，2012, 19(10): 732-743.
|
1/5
微信公眾號